Keyphrases
Neuraminidase Inhibitors
100%
Influenza
100%
Oseltamivir
100%
Healthy Adults
100%
Healthy children
100%
Clinical Reports
50%
Intention-to-treat
33%
Zanamivir
33%
Confidence Interval
25%
Individual Patient Data
25%
Odds Ratio
16%
Hospitalization
16%
Alleviation
16%
Placebo Groups
16%
Treatment Trials
16%
Publication Bias
16%
Reporting Bias
16%
Pre-analysis Plan
16%
Cochrane Review
8%
Older People
8%
Randomized Controlled Trial
8%
High Risk
8%
Trial Registries
8%
Statistical Analysis Plan
8%
Trial Results
8%
All Ages
8%
GlaxoSmithKline
8%
Age Groups
8%
Clinical Trial Data
8%
Influenza-like Illness
8%
Illness Symptoms
8%
Respiratory Disease
8%
Event Rate
8%
Population Data
8%
CONSORT Statement
8%
Attrition Bias
8%
Lack of Information
8%
U.S. Food
8%
Mechanism of Action
8%
Randomized Methods
8%
Publicly Available
8%
Method Analysis
8%
Patient Data
8%
Small number of Studies
8%
Place of Residence
8%
Influenza Season
8%
Group Events
8%
Antibody Production
8%
Viral Transmission
8%
Validity Problem
8%
Evidence Support
8%
Drug Indications
8%
Local Site
8%
Placebo-controlled Randomized Trial
8%
Review Update
8%
Public Health Risk
8%
Possible Mechanisms
8%
Local Community
8%
Blinding Procedures
8%
Care Homes
8%
Antibody Response
8%
Infected Population
8%
In Care
8%
Protocol Analysis
8%
National Government
8%
Information-centric
8%
Outstanding Issues
8%
Population Analysis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Sialidase Inhibitor
100%
Oseltamivir
100%
Normal Human
100%
Clinical Study
58%
Relenza
33%
Placebo
25%
Randomized Controlled Trial
16%
Clinical Trial
8%
Respiratory Tract Disease
8%
Flu Like Syndrome
8%
Base
8%
Pamicogrel
8%
Virus Transmission
8%